Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.56 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14161697 | 0.86 | GRIN2B (0.76) | GRIN2BL3MBTL1MBTD1L3MBTL3ALDH1A1 | |
| SCHEMBL8618958 | 0.84 | HRH3 (0.51) | GRIN2BL3MBTL1L3MBTL3DRD2DRD3 | |
| SCHEMBL8911504 | 0.83 | MBTD1 (0.52) | GRIN2BL3MBTL1MBTD1L3MBTL3DRD2 | |
| SCHEMBL11980117 | 0.81 | GRIN2B (0.65) | GRIN2BL3MBTL1MBTD1L3MBTL3ALDH1A1 | |
| SCHEMBL13240777 | 0.81 | GRIN2B (0.65) | GRIN2BL3MBTL1MBTD1L3MBTL3ALDH1A1 | |
| SCHEMBL737747 | 0.81 | GRIN2B (0.65) | GRIN2BL3MBTL1MBTD1L3MBTL3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL29224139 | 0.81 | MBTD1 (0.50) | GRIN2BL3MBTL1MBTD1L3MBTL3DRD2 | |
| SCHEMBL30387 | 0.81 | GAA (0.56) | GRIN2BL3MBTL1MBTD1L3MBTL3ALDH1A1 | |
| SCHEMBL12662876 | 0.80 | L3MBTL3 (0.73) | GRIN2BL3MBTL1MBTD1L3MBTL3ALDH1A1 | |
| SCHEMBL13648728 | 0.79 | L3MBTL3 (0.72) | GRIN2BL3MBTL1MBTD1L3MBTL3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10695449-B2 | Catalytic radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190054198-A1 | CATALYTIC RADIOFLUORINATION | THE GENERAL HOSPITAL CORPORATION | 2019-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190054198-A1 | CATALYTIC RADIOFLUORINATION | KCNJ5, KCNQ5, KCNK18 | GRIN2B 4487/4885L3MBTL1 3388/4885MBTD1 4617/4885 |
| US-10695449-B2 | Catalytic radiofluorination | KCNJ5, KCNQ5, KCNK18 | GRIN2B 4487/4885L3MBTL1 3388/4885MBTD1 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.